Skip to main content
SpringerLink
Log in

The anti-tumour efficacy of human recombinant interleukin 2

Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Experiments were designed to test what percentage of experimental MC-induced murine sarcomas were sensitive to the local tumour inhibitory effect of IL-2 and whether any correlation existed between the sensitivity of these sarcomas to the immunotherapeutic effect of IL-2 and their susceptibility to the cytolytic effect of IL-2-activated killer cells. It was found that the sensitivity of MC-induced sarcomas to local IL-2 immunotherapy was a general phenomenon. Repeated peri-tumoural injections of RIL-2 inhibited the growth of five (MC11, MC13, MC14, MC15, MC16) out of six sarcomas in syngeneic mice. The sixth murine sarcoma (MC12) was found to be resistant to the tumour inhibitory effect of IL-2. Similarly, five (MC11, MC13, MC14, MC15, MC16) out of six murine sarcoma cell lines were sensitive to the cytolytic effect of IL-2-activated syngeneic killer spleen cells when examined in vitro, whereas the sixth (MC12) sarcoma cell line was resistant. These results suggest that LAK cells represent the effector cell mechanism responsible for the anti-tumour efficacy of local IL-2 immunotherapy and that in vitro testing of sensitivity to the LAK cell-mediated cytolysis may be used to detect tumours responding to IL-2 immunotherapy in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL-2:

interleukin 2

RIL-2:

human recombinant interleukin 2

LAK:

lymphokine-activated killer

MC:

3-methylcholanthrene

B10:

C57BL/10ScSnPh

MSV:

murine sarcoma virus (Harvey)

MEM:

minimal essential medium

References

  1. Bubeník J, Turano A, Fadda G (1969) Prevention of carcinogenesis by murine sarcoma virus (Harvey) following injections of immune sera during the latent period. Int J Cancer 4:648

    Google Scholar 

  2. Bubeník J, Indrová M, Němečková Š, Malkovský M, von Broen B, Pálek V, Anderlíková J (1978) Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests. Int J Cancer 21:348

    Google Scholar 

  3. Bubeník J, Jandlová T, Šuhajová E, Malkovský M (1979) Cell surface adhesiveness of mouse sarcoma lines evaluated by Latex particle adherence assay: Correlation with growth behavior and electrophoretic mobility. Neoplasma 26:499

    Google Scholar 

  4. Bubeník J, Perlmann P, Indrová M, Šímová J, Jandlová T, Neuwirt J (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 14:205

    Google Scholar 

  5. Bubeník J, Indrová M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcová A (1985) Tumour inhibitory effect of TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 19:57

    Google Scholar 

  6. Bubeník J, Kieler J, Indrová M (1986) Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice. Folia Biol (Praha) 32:209

    Google Scholar 

  7. Bubeník J, Kieler J, Tromholt V, Steven K, Indrová M, Toulcová A (1986) Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2. Folia Biol (Praha) 32:183

    Google Scholar 

  8. Cheever MA, Thompson JA, Kern DE, Greenberg PD (1985) Interleukin 2 (IL 2) administered in vivo: Influence of IL 2 route and timing on T cell growth. J Immunol 134:3895

    Google Scholar 

  9. Donohue JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203

    Google Scholar 

  10. Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel RM, Jaffe ES, Rosenberg SA (1984) In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res 44:1380

    Google Scholar 

  11. Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA (1985) Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 135:3623

    Google Scholar 

  12. Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735

    Google Scholar 

  13. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134:157

    Google Scholar 

  14. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer M-C, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. II. Half-life, immunologic effect, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865

    Google Scholar 

  15. Mühlradt PF, Opitz HG (1982) Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. Eur J Immunol 12:983

    Google Scholar 

  16. Mulé JJ, Shu S, Rosenberg SA (1985) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 135:646

    Google Scholar 

  17. Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1984) Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int J Cancer 34:359

    Google Scholar 

  18. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Flemingovo nám. 2, 166 37, Prague, Czechoslovakia

    J. Bubeník & M. Indrová

Authors
  1. J. Bubeník
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Indrová
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bubeník, J., Indrová, M. The anti-tumour efficacy of human recombinant interleukin 2. Cancer Immunol Immunother 24, 269–271 (1987). https://doi.org/10.1007/BF00205642

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00205642

Keywords

Search

Navigation